Effect of Zaprinast on Nitric Oxide Levels in Serum and Aortic Tissue

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 26, Issue 1, 2004, Pages 19-24

  Ibrahim, M A ^a   Asai, H ^a   Satoh, S ^a   Satoh, N ^a   Ueda, Shiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Blood pressure; Nitric oxide (NO); Phosphodiesterase inhibitors (PDE 5); Zaprinast

Indexed keywords

ARGININE; CYCLIC GMP; GUANYLATE CYCLASE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; PHOSPHODIESTERASE; PHOSPHODIESTERASE V INHIBITOR; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; REGULATORY MECHANISM;

ANIMALS; AORTA; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NITRIC OXIDE; PURINONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 1542285862     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2004.26.1.793468     Document Type: Article

References (38)

1. Griffith, O.W., Kilbourn, R.G. Design of nitric oxide synthase inhibitors and their use to reverse hypotension associated with cancer immunotherapy. Adv Enzyme Regul 1997, 37: 171-94.
2. Moncada, S., Palmer, R.M.J., Higgs, E.A. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43: 109-42.
3. Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992, 6: 3051-64.
4. Bredt, D.S., Sunder, S.H. Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990, 87: 682-5.
5. Lyons, C.R., Orloff, G.J., Cunningham, J.M. Molecular cloning and functional expression of inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem 1992, 267: 6370-4.
6. Forstermann, U.A., Mulsh, A., Bohme, A., Busse, R. Stimulation of soluble guanylate cyclase by an acetylcholine-induced endothelium-derived factor from rabbit and canine arteries. Cir Res 1986, 58: 531.
7. Shikano, K., Long, C.J., Ohlstein, E.H., Berkowitz, B.A. Comparative pharmacology of endothelium-derived relaxing factor and nitric oxide. J Pharmacol Exp Ther 1988, 247: 873.
8. McDonald, L.J., Murad, F. Nitric oxide and cGMP signaling. Adv Pharmacol 1995, 34: 263-75.
9. Ignarro, L.J., Fukuto, J.M., Griscavage, J.M., Rogers, N.E., Byrns, R.E. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci USA 1993, 90: 8103-7.
10. Kuhn, M., Otten, A., Frolich, J.C., Forstermann, U. Endothilial cyclic GMP and cyclic AMP do not regulate the release of endothelium-derived relaxing factor/nitric oxide from bovine aortic endothelial cells. J Pharmacol Exp Ther 1991, 256: 677-82.
11. Hallen, K., Olgart, C., Gustafsson, L.E., Wiklund, N.P. Modulation of neuronal nitric oxide release soluble guanylyl cyclase in guinea pig colon. Biochem Biophys Res Commun 2001, 280: 1130-4.
12. Vaziri, N.D., Wang, X.Q. cGMP-mediated negative-feedback regulation at endothelial nitric oxide synthase expression by nitric oxide. Hypertension 1999, 34: 1237-41.
13. Beshay, E., Prud'homme, G.J. Inhibitors of phosphodiesterase III or IV suppress islet-cell nitric oxide production. Lab Invest 2001, 81: 1109-17.
14. Takahashi, T., Kanda, T., Sumini, H. et al. Type V phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotalin-induced pulmonary hypertension. Res Exp Med 1998, 197: 319-28.
15. Thompson, W.J. Cyclic-nucleotide phosphodiesterases-pharmacology, biochemistry and function. Pharmacol Ther 1991, 51: 13-33.
16. Cobin, J.D. Francis, S.H. Cyclic GMP phosphodiesterase-5 target of sildenafil. J Biol Chem 1999, 274: 13729-32.
17. Fawcett, L., Baxendale, R., Stacey, P. et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE II A. Proc Natl Acad Sci USA 2000, 97: 3702-7.
18. Lincoln, T.M., Hall, C.L., Park, C.R., Corbin, J.D. Guanosine 3′,5′-cyclic monophosphate binding proteins in rat tissue. Proc Natl Acad Sci USA, 1976, 73: 2559-63.
19. Francis, S.H., Lincoln, T.M., Corbin, J.D. Characterization of a novel cGMP bindind protein from rat lung. J Biol Chem 1980, 255: 620-6.
20. Francis, S.H., Corbin, J.D. Purification of cGMP-binding protein phosphodiesterase from rat lung. Methods Enzymol 1988, 159: 722-59.
21. Thomas, M.K., Francis, S.H., Corbin, J.D. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 1990, 265: 14964-70.
22. Broughton, B.J., Chaplen, P., Knowles, P. et al. New inhibitor of reagin-mediated anaphylaxis. Nature 1974, 251: 650-2.
23. Bergstrand, H., Lundquist, B., Schurmann, A. Effects a antiallergic agents, compound 48/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3′,5′ -monophosphate and guanosine cyclic 3′,5′-monophosphate phosphodiesterases. Mol Pharmacol 1977, 13: 38-43.
24. Bouman, A., Drummond, A.H. Cyclic GMP mediates neurogenic relaxation in the bovine retracted penis. Br J Pharmacol 1984, 81: 665-74.
25. Trigorocha, F., Aronson, W.J., Hohenfellner, M., Ignaro, L.J., Rajfer, J., Lue, T.F. Nitric oxide and cyclic GMP-mediators of pelvic nerve-stimulated erection in dogs. Am J Physiol 1993, 264: H419-22.
26. Lugnier, C., Schoeffer, P., Le Bec, A., Strouthou, E., Stoclet, J.C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 1986, 35: 1751-3.
27. Ahn, H.S., Crim, W., Romano, M., Sybertz, E., Pitts, B. Effect of selective inhibitors of cyclic nucleotide phosphodiesterases of rabbit aorta. Pharmacol 1989, 38: 3331-9.
28. Weishaar, R.E., Kobylarz-Singer, D.C., Keiser, J., Haleen, S.J., Major, T.C., Rapundalo, S. Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of natriuretic factor. Hypertension 1990, 15: 528-40.
29. Trapani, A.J., Smith, G.L., McGraw, D.E., McMahon, E.G., Blaine, E.H. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J Pharmacol Exp Ther 1991, 258: 269-74.
30. Dundore, R.L., Habeeb, P.G., Pratt, P.F., Becker, L.T., Clas, D.M., Buchholz, R.A. Differential hemodynamic responses to selective inhibitors of cyclic nucleotide phophodiesterases in conscious rats. J Cardiovasc Pharmacol 1992, 19: 937-44.
31. McMahon, E.G., Palmo, M.A. Metha, P., Olins, G.M. Depressor and natriuretic effects of MandB 22, 948, a guanosine cyclic 3′ ,5-monophosphate-selective phosphodiesterase inhibitor. J Pharmacol Exp Ther 1989, 251: 1000-5.
32. Sayago C.M., Beierwaltes, W.H. Nitric oxide synthase and cGMP-mediated stimulation of renin secretion. Am J Physiol Regul Integr Comp Physiol 2001, 281: R1146-51.
33. Dundore, R.L., Clas, D.M., Wheeler, L.T. et al. Zaprinast increases cGMP levels in plasma and in aortic tissue of rats. Eur J Pharmacol 1993, 249: 937-44.
34. Dundore, R.L., Pratt, P.F., O'Connor, B., Buchholz, R.A., Pagani, E.D. N-Nitro-L-arginine attenuates the accumulations of aortic cyclic GMP and the hypotension produced by zaprinast. Eur J Pharmacol 1991, 200: 83-6.
35. Griffith, T.M., Hughes Edwards, D., Lewis, M.J., Newaby, A.C. Henderson, A.H. The nature of endothelium-derived vascular relaxant factor. Nature 1984, 350: 46.
36. Choi, S.H., Choi, D.H., Song, K.S., Shin, K.H., Chun, B.G. Zaprinast, an inhibitor of cGMP-selective PDEs, enhances the secretion of TNF-α and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells. J Neurosci Res 2002, 67: 411-21.
37. Francis, S.H., Turko, T.V., Corbin, J. D. Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog Nucleic Acid Res Mol Biol 2001, 65: 1-52.
38. Hosogai, N., Seki, J., Goto, T. Reciprocal regulation of cGMP content by cGMP-PDEs and guanylate cyclase in SHR with CsA-induced nephrotoxicity. Br J Pharmacol 2001, 134: 995-1002.